ArticleDiscover oncology2025
Research trends and prospects of Circulating tumor DNA associated with colorectal cancer: a bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis (1997-2025).Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recent research has highlighted ctDNA as a crucial tool for screening, monitoring, and treating colorectal cancer, gaining significant attention. This study aims to map the research landscape via bibliometric analysis, identifying future trends and key areas of interest. We collected articles and reviews on ctDNA and colorectal cancer from the Web of Science Core Collection and Scopus, conducting bibliometric analysis and visualization using VOSviewer, CiteSpace, and R packages. A total of 1,730 publications were included in the bibliometric analysis. Of these, 325 were unique to WOS and 639 were unique to SCOPUS. The United States and China led in publication volume with 555 and 306 papers, respectively, while the United States and Italy had the highest citation counts, with 39,142 and 21,417 citations, respectively. The University of Texas MD Anderson Cancer Center was the most prolific institution. The journals Cancers and Frontiers in Oncology were the most frequently published. Bardelli A stood out as the most prolific and cited author. Cluster analysis revealed trending topics such as "minimal residual disease," "adjuvant chemotherapy," and "recurrence." This bibliometric analysis highlights significant advancements and emerging trends in the clinical application of ctDNA for colorectal cancer. The identified hotspots deserve further attention from researchers in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.